BD Diagnostics has entered into an agreement with Biodiversity to develop a molecular diagnostic menu on the BD MAX System to monitor infection in immunocompromised patients.
The assays introduced under the partnership for the BD MAX System expands testing capabilities for molecular laboratories with the ability to run many different assays and samples simultaneously, which tends to faster testing results and earlier diagnosis for patients.
BD Diagnostics – Diagnostic Systems president Tom Polen said this collaboration combines the BD MAX System’s automation and open system capabilities with Biodiversity’s broad portfolio and track record at bringing to market molecular assays for the management of transplant patients.
Biodiversity CEO Giovanni Mantero said at Biodiversity, their extensive assay experience in molecular transplant diagnostics is positioned to capitalize on the technological advantages of the BD MAX System, making it possible to deliver a major advance in terms of efficiency, accuracy and ease-of-use for laboratories.
BD Diagnostics claims that assays developed through this collaboration are intended to be CE marked for sale and distribution in Europe, with future expansion to additional regions.